Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTRENASDAQ:LFSTNASDAQ:VCYTNASDAQ:WGS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTREFortrea$5.45-0.2%$5.21$3.97▼$28.41$494.13M1.591.88 million shs1.95 million shsLFSTLifeStance Health Group$4.93-2.2%$6.04$4.64▼$8.61$1.96B1.221.62 million shs3.08 million shsVCYTVeracyte$26.82+0.2%$29.16$19.73▼$47.32$2.10B2.09911,745 shs687,335 shsWGSGeneDx$64.43+0.6%$76.73$24.91▼$117.75$1.83B1.94788,831 shs685,326 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTREFortrea-0.18%+0.37%+22.47%-37.86%-76.65%LFSTLifeStance Health Group-2.18%-11.96%-15.58%-27.71%-6.81%VCYTVeracyte+0.22%-3.97%-7.52%-15.77%+25.27%WGSGeneDx+0.61%-8.38%-9.28%-33.38%+133.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTREFortrea3.8984 of 5 stars3.91.00.00.02.80.83.8LFSTLifeStance Health Group2.6826 of 5 stars3.42.00.00.02.82.50.6VCYTVeracyte4.0984 of 5 stars4.41.00.04.32.80.00.6WGSGeneDx3.6791 of 5 stars3.42.00.00.01.95.01.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTREFortrea 1.86Reduce$15.00175.23% UpsideLFSTLifeStance Health Group 2.83Moderate Buy$8.5072.41% UpsideVCYTVeracyte 2.70Moderate Buy$40.9052.50% UpsideWGSGeneDx 2.75Moderate Buy$86.7534.64% UpsideCurrent Analyst Ratings BreakdownLatest FTRE, VCYT, LFST, and WGS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025LFSTLifeStance Health GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.505/22/2025FTREFortreaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/15/2025WGSGeneDxGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$88.005/14/2025FTREFortreaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/14/2025FTREFortreaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.005/14/2025FTREFortreaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.005/13/2025FTREFortreaBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.005/9/2025WGSGeneDxJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$80.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/2/2025FTREFortreaTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$7.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTREFortrea$2.70B0.18$1.57 per share3.47$15.19 per share0.36LFSTLifeStance Health Group$1.25B1.53$0.04 per share127.10$3.78 per share1.30VCYTVeracyte$445.76M4.71$1.04 per share25.81$15.17 per share1.77WGSGeneDx$305.45M6.02$1.03 per share62.58$8.75 per share7.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTREFortrea-$328.50M-$8.79N/A4.260.37-29.43%2.84%1.06%8/11/2025 (Estimated)LFSTLifeStance Health Group-$57.44M-$0.10N/AN/AN/A-2.78%-2.47%-1.69%8/14/2025 (Estimated)VCYTVeracyte$24.14M$0.4165.4237.25N/A7.13%6.14%5.60%8/5/2025 (Estimated)WGSGeneDx-$52.29M-$1.41N/A30.83N/A-11.69%10.17%5.51%7/29/2025 (Estimated)Latest FTRE, VCYT, LFST, and WGS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025FTREFortrea-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million4/30/2025Q1 2025WGSGeneDx$0.11$0.28+$0.17-$0.23$79.90 million$87.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTREFortreaN/AN/AN/AN/AN/ALFSTLifeStance Health GroupN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/AWGSGeneDxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTREFortrea1.220.970.97LFSTLifeStance Health Group0.191.471.47VCYTVeracyteN/A5.104.78WGSGeneDx0.203.253.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTREFortreaN/ALFSTLifeStance Health Group85.50%VCYTVeracyteN/AWGSGeneDx61.72%Insider OwnershipCompanyInsider OwnershipFTREFortrea0.38%LFSTLifeStance Health Group3.20%VCYTVeracyte1.40%WGSGeneDx29.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTREFortrea15,50090.50 million90.16 millionOptionableLFSTLifeStance Health Group10,218388.88 million376.43 millionOptionableVCYTVeracyte79078.32 million77.22 millionOptionableWGSGeneDx1,20028.53 million20.09 millionOptionableFTRE, VCYT, LFST, and WGS HeadlinesRecent News About These CompaniesRosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGSJune 18 at 7:45 PM | prnewswire.comGENEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the FirmJune 17 at 9:00 PM | globenewswire.com3 Medical Services Stocks Capitalizing on the Healthcare AI BoomJune 16 at 12:11 PM | zacks.comWGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law FirmJune 16 at 11:41 AM | prnewswire.comOversold Conditions For GeneDx Holdings (WGS)June 15, 2025 | nasdaq.comGeneDx, WGS, to rise 3,300% at the open - no, don’t do anything about itJune 14, 2025 | dhakatribune.comAssenagon Asset Management S.A. Lowers Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)June 14, 2025 | marketbeat.comINVESTIGATION ALERT: Edelson Lechtzin LLP is investigating GeneDx Holdings Corp. (NASDAQ: WGS) and Encourages Investors with Substantial Losses to Contact the FirmJune 13, 2025 | prnewswire.com15,937 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Bought by Harbor Capital Advisors Inc.June 13, 2025 | marketbeat.comWGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law FirmJune 12, 2025 | prnewswire.comRosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation – WGSJune 12, 2025 | businesswire.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12, 2025 | schaeffersresearch.comGeneDx (NASDAQ:WGS) Trading Down 3.8% - Here's What HappenedJune 12, 2025 | marketbeat.comGAMMA Investing LLC Grows Stock Holdings in GeneDx Holdings Corp. (NASDAQ:WGS)June 12, 2025 | marketbeat.comWGS Investors Have Opportunity to Join GeneDx Holdings Corp. Fraud Investigation with the Schall Law FirmJune 11, 2025 | businesswire.comGeneDx Holdings Corp. (NASDAQ:WGS) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCJune 10, 2025 | marketbeat.comKevin Feeley Sells 370 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) StockJune 4, 2025 | marketbeat.comInsider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 370 Shares of StockJune 4, 2025 | insidertrades.comBank of America Corp DE Lowers Position in GeneDx Holdings Corp. (NASDAQ:WGS)June 4, 2025 | marketbeat.comWellington Management Group LLP Invests $10.82 Million in GeneDx Holdings Corp. (NASDAQ:WGS)June 3, 2025 | marketbeat.comSquarepoint Ops LLC Sells 34,840 Shares of GeneDx Holdings Corp. (NASDAQ:WGS)June 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFTRE, VCYT, LFST, and WGS Company DescriptionsFortrea NASDAQ:FTRE$5.45 -0.01 (-0.18%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$5.45 0.00 (0.00%) As of 06/18/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.LifeStance Health Group NASDAQ:LFST$4.93 -0.11 (-2.18%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$5.04 +0.11 (+2.13%) As of 06/18/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.Veracyte NASDAQ:VCYT$26.82 +0.06 (+0.22%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$26.78 -0.04 (-0.15%) As of 06/18/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.GeneDx NASDAQ:WGS$64.43 +0.39 (+0.61%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$64.02 -0.41 (-0.63%) As of 06/18/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
